On February 23, 2024, ImmunoPrecise Antibodies Ltd. entered into a Sales Agreement with Clear Street LLC to potentially sell up to $60 million of common shares. The sales, if made, will be conducted at the market as defined by the relevant rules, but the company is not obligated to sell any shares.